Nearly 30 representatives yesterday urged House leaders to modify in the next COVID-19 response package impending thresholds for qualifying participants in Advanced Alternative Payment Models, which they said threaten to “derail” the movement to value-based care under the Medicare Access and CHIP Reauthorization Act.

“It has become clear that COVID-19 will make it more challenging for many of these providers to meet the law’s current thresholds due to shifts in care,” the House members wrote. “According to data recently released by the Centers for Medicare & Medicaid Services, on average, providers missed even the current QP threshold (50%) and are nowhere near the heightened threshold (75%) required by statute in 2021. It is critical for seniors that APMs continue in 2021 and beyond. Providers participating in APMs are conducting care coordination strategies that are needed now more than ever.”

Reps. Suzan DelBene, D-Wash., Roger Marshall, R-Kan., Peter Welch, D-Vt., and Darin LaHood, R-Ill., spearheaded the letter with support from AHA and other national hospital and physician organizations.

Headline
The AHA May 20 provided comments to the House Energy and Commerce Subcommittee on Health for a hearing on the physician fee schedule, the Medicare Access…
Headline
The Centers for Medicare & Medicaid Services has released its fiscal year 2025 Program for Evaluating Payment Patterns Electronic Reports, or PEPPERs, for…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…